Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

NCT04673214 PHASE3 COMPLETED Results posted

The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call

Details

Lead sponsor	Gilberto Cruz Arteaga
Phase	PHASE3
Status	COMPLETED
Enrolment	114
Start date	Wed Dec 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Covid19

Interventions

• Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
• Azithromycin / Ribaroxaban / Paracetamol

Countries

Mexico